Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect Novo Nordisk's cagrilintide shows promise in Phase 3 trial Alan Nafiev posted on the topic LinkedIn Novo Nordisk files for FDA approval of CagriSema, the first once weekly combination of GLP1 and amylin analogues for weight management Development of Cagrilintide, a Long Acting Amylin Analogue Journal of Medicinal Chemistry Novo Nordisk's CagriSema Drug Trial Data Falls Short Again Shares Plunge by 8 Percent